Related Experiment Video
Updated: Aug 21, 2026
Technique of Conjunctival Biopsy and Direct Immunofluorescence for Diagnosing Mucous Membrane Pemphigoid
Published on: June 17, 2025
Rituximab in primary conjunctiva lymphoma
Pier Luigi Zinzani1, Lapo Alinari, Vittorio Stefoni
1Institute of Hematology and Medical Oncology Seràgnoli, University of Bologna, Bologna, Italy. plzinzo@med.unibo.it
Insights
Rituximab effectively treated conjunctival lymphoma, achieving a complete response. The patient experienced no acute or late eye toxicity, demonstrating a favorable safety profile.
Area of Science:
- Ophthalmology
- Oncology
- Hematology
Background:
- Primary conjunctiva lymphoma is a rare neoplastic proliferation affecting the eye.
- Treatment options for conjunctival lymphoma can involve radiation, chemotherapy, or targeted therapies.
- Rituximab, a monoclonal antibody, targets B-cells and has shown efficacy in various lymphomas.
Observation:
- A single patient with primary conjunctiva lymphoma was treated with conventional dose rituximab.
- The treatment was administered in an outpatient setting.
- Ocular and systemic health of the patient was monitored.
Findings:
- The patient achieved a complete response following rituximab treatment.
- No acute local toxicities related to the eye were observed.
- No late local toxicities affecting the eye were reported during follow-up.
Implications:
- Conventional dose rituximab may be a safe and effective treatment for primary conjunctiva lymphoma.
- This case highlights the potential of targeted therapy in ocular adnexal lymphomas.
- Further studies are warranted to confirm these findings in a larger patient cohort.
Abstract:
Our experience with a patient with a primary conjunctiva lymphoma who was treated with conventional dose of rituximab obtaining a complete response without acute and late local toxicity for the eye.
